<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606539</url>
  </required_header>
  <id_info>
    <org_study_id>GTN and surgery</org_study_id>
    <nct_id>NCT02606539</nct_id>
  </id_info>
  <brief_title>Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms</brief_title>
  <acronym>SVCGTN</acronym>
  <official_title>Primary Surgery Plus Single Course Methotrexate Versus Primary Methotrexate for Treatment of Gestational Trophoblastic Neoplasms in Low Risk Cases Above 40y: a Randomized Controled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maher elesawi kamel elesawi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational trophoblastic neoplasm affect women and is sensitive to chemotherapy especially
      methotrexate and the investigators try to find a role of surgery plus methotrexate instead of
      multiple doses and cycles of chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational trophoblastic neoplasm affect women and is sensitive to chemotherapy espechialy
      methotrexate and the investigators try to find a role of surgery plus mehotrexate instead of
      multiple doses and cycles of chemotherapy that affect the patient quality of life and
      complication related to both line of management and time of decrease of B-hcg.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of primary chemotherapy courses till B-hCG reach less than 5 MU/ML</measure>
    <time_frame>1-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life( questionairre)</measure>
    <time_frame>1-6 months</time_frame>
    <description>pain scale from zero to 11, return to ordinary activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications from management</measure>
    <time_frame>1-6 months</time_frame>
    <description>renal, hepatic impairments, anemia,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time interval for B-hCG reach less than 5 MU/ML</measure>
    <time_frame>1-6 months</time_frame>
    <description>the time taken for B-hCG to reach below 5 MU/ML</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gestational Trophoblastic Neoplasms</condition>
  <arm_group>
    <arm_group_label>surgery and methotrxate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will be treated by total abdominal hystrectomy(after written consent laparatomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg alternating with calcium folinate 0.1 mg/kg until normalization of B-HCG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrxate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will be treated by multiple courses of methotrexate( antifolate) 1mg/kg every 14 days each one alternating in every otherday with calcium folinate 0.1 mg/kg till normalization of B-HCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total abdominal hysterectomy and methotrexate</intervention_name>
    <description>After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)</description>
    <arm_group_label>surgery and methotrxate</arm_group_label>
    <other_name>surgery and chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate plus folinic acid alone</intervention_name>
    <description>methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG</description>
    <arm_group_label>methotrxate</arm_group_label>
    <other_name>chemotharapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  females

          -  40 years or more

          -  plateau or rising B- hCG titre

          -  without distant metastasis

          -  WHO score is less than 7

        Exclusion Criteria:

          -  less than 40 years

          -  distant metastasis to lung and liver

          -  chronic medical diseases

          -  WHO score is more than 7
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reda hemida, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>maher elesawi, Msc</last_name>
    <phone>01016103662</phone>
    <email>maherelesawi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura University Hospital</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maher E Kamel elesawi, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maher Elesawi Kamel Elesawi</name>
      <address>
        <city>Mit Ghamr</city>
        <state>Eldakahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maher Elesawi, MD student</last_name>
      <phone>01016103662</phone>
      <email>maherelesawi@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Reda Hemida, MD</last_name>
      <phone>01008622573</phone>
      <email>redaelshouky@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Maher elesawi kamel elesawi</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>gestaional trophoblastic neoplasm</keyword>
  <keyword>hystrectomy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>methotrxate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

